Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with rendu‐osler disease

Abstract

The intranasal spray application of 50 mg bevacizumab was found to be an effective symptomatic treatment over a period of 2 months for patients with a pretreatment ESS of <7, with no adverse effects being noted.